Development of a risk score for predicting the benefit versus harm of extending dual antiplatelet therapy beyond 6 months following percutaneous coronary intervention for stable coronary artery disease

BACKGROUND: Decisions on dual antiplatelet therapy (DAPT) duration should balance the opposing risks of ischaemia and bleeding. Our aim was to develop a risk score to identify stable coronary artery disease (SCAD) patients undergoing PCI who would benefit or suffer from extending DAPT beyond 6 month...

Descripción completa

Detalles Bibliográficos
Autores principales: Witberg, Guy, Plakht, Ygal, Bental, Tamir, Feldman, Becca S., Leventer-Roberts, Maya, Levi, Amos, Gabay, Hagit, Balicer, Ran, Gerber, Yariv, Kornowski, Ran
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Public Library of Science 2019
Materias:
Research Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6375573/
https://www.ncbi.nlm.nih.gov/pubmed/30763340
http://dx.doi.org/10.1371/journal.pone.0209661

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6375573/
https://www.ncbi.nlm.nih.gov/pubmed/30763340
http://dx.doi.org/10.1371/journal.pone.0209661

Ejemplares similares